Page 71 - Aet News Today

When asked to list their top health and wellbeing priorities over the next three years, 69% of employers said managing their health plan’s costs and budgeting, while 63% said enhancing mental health programs, a new survey shows.

With its new handheld ultrasound device, Exo is seeking to take point-of-care ultrasound beyond just the emergency medicine field — into areas like urgent care, primary care and the home. Kurt Hammond, Exo's chief commercial officer, said that the device sets itself apart from other handheld ultrasound devices, such as those sold by GE, Philips and Butterfly Network, because its AI does a better job of making the ultrasound process quick and easy for providers.

Cedars-Sinai published research in JAMA Cardiology this week on a algorithm it developed to detect atrial fibrillation in people not yet showing symptoms. The study found that the AI model does a good job of identifying hidden signals in common medical diagnostic testing and could help physicians better prevent strokes and other heart-related complications in people with atrial fibrillation.

After paying $4 billion up front, Merck will share in the development and commercialization of three Daiichi Sankyo cancer drugs in the red-hot field of antibody drug conjugates, or ADCs. The most advanced of them is on track for an FDA submission in 2024.

FOLX Health is now in-network with insurers, including Blue Shield of California. The company serves the LGBTQIA+ community and offers virtual primary care, one-on-one therapy, mental health medication management, hormone replacement therapy, pre-exposure prophylaxis and care navigation.

We must prioritize early screening and diagnosis to facilitate timely interventions, prevent the progression to advanced liver disease and, ultimately, help save the lives of 1 in 10 Americans.

Investing in Friction-reducing tactics such as community building and providing benefits, training, and personalized support to employees will yield compounding long-term benefits while reducing churn rate.

Annual family premiums for employer-sponsored coverage reached $23,968 in 2023, according to a new KFF survey. Of that family premium total, workers are contributing $6,575 annually.

FDA approval of UCB’s Bimzelx gives the Belgian drugmaker a contender in the crowded plaque psoriasis therapies market. In the rare disease generalized myasthenia gravis, the agency approved Zilbrysq, a UCB drug with advantages over two blockbuster AstraZeneca drugs addressing the same target.

In an upcoming webinar, learn how informed awareness can help hospitals overcome their most challenging operational challenges to simultaneously improve efficiency, staff engagement and satisfaction, quality of care, and profitability.